

Disclosures

Personal Commercial (28)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
3ive Labs, LLC	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Abbott	Research/Research Grants	Significant (>= \$5,000)	Acute Coronary Syndromes
Abbott Laboratories	Research/Research Grants	Significant (>= \$5,000)	Arrhythmias and Clinical EP
Ablative Solutions, Inc	Research/Research Grants	Significant (>= \$5,000)	Invasive CV Angio and Interventions
AHA	Research/Research Grants	Significant (>= \$5,000)	Acute Coronary Syndromes
Biocardia	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
BIOTRONIK, INC.	Research/Research Grants	Significant (>= \$5,000)	Arrhythmias and Clinical EP
Caladrius Biosciences	Research/Research Grants	Significant (>= \$5,000)	Stable Ischemic Heart Disease
CSL Behring LLC (CSLB)	Research/Research Grants	Significant (>= \$5,000)	Acute Coronary Syndromes
DCRI	Other - Multidisciplinary committee providing input to PCORI funded HERO studies	Modest (< \$5,000)	Prevention
DOD	Research/Research Grants ‡ WARRIOR	Significant (>= \$5,000)	Stable Ischemic Heart Disease
Duke University/PCORI	Research/Research Grants ‡ ADAPTABLE	Significant (>= \$5,000)	Stable Ischemic Heart Disease
Evaheart, Inc	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
GE Healthcare Ltd. and its Affiliates	Research/Research Grants	None (\$0)	Stable Ischemic Heart Disease
LivaNova USA, Inc.	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Medtronic, Inc	Research/Research Grants	Significant (>= \$5,000)	Arrhythmias and Clinical EP
Medtronic, Inc.	Research/Research Grants	Modest (< \$5,000)	Arrhythmias and Clinical EP
Milestone pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	Arrhythmias and Clinical EP
NIH	Research/Research Grants	Significant (>= \$5,000)	Stable Ischemic Heart Disease
NIH	Research/Research Grants	Significant (>= \$5,000)	Stable Ischemic Heart Disease
nih	Research/Research Grants	Significant (>= \$5,000)	Stable Ischemic Heart Disease
NIH	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
NIH/Pittsburgh/RTI	Research/Research Grants ‡ ACTIV 4 B- PI One Florida Consortium Investigators	Significant (>= \$5,000)	Other
Novartis	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Novo Nordisk Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	Other
PCORI	Research/Research Grants	Significant (>= \$5,000)	Other
TIMI Study Group and AstraZeneca	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
XyloCor Therapeutics, Inc.	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (2)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
----------------------------	-----------------------	--------------------	---------------

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
American College of Cardiology	Other - Serve on ACC Governance Committee	None (\$0)	
Preventative Cardiovascular Nurses Association	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	<i>Prevention</i>

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (1)

Funding Source	Institutional Compensation Level
Preventative Cardiovascular Nurses Association	None (\$0)

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/12/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/12/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 10/12/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 10/12/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.